Abstract
Transthyretin amyloidosis represents the most common type of amyloidosis involving heart. Heart failure and arrhythmias are the most frequent manifestations of the disease.
In majority of the patients the diagnosis can be established based on the non-invasive imaging methods and endomyocardial biopsy is usually not needed. Heart failure treatment is usually based on loop diuretics and mineralocorticoid receptor blockers administration.
Specific treatment of transthyretin cardiac amyloidosis consists of gene expression silencers, transthyretin stabilizers and amyloid extractors. Tafamidis represents currently the most promising drug in the treatment of transthyretin cardiac amyloidosis.
This drug will be hopefully available in clinical practise in near future.